A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1608 | Th1131 | Taliglucerase Alfa | EFARPCIPKSFGYSSVVCVC Full view | 504 | Ia | Hormonal | Elelyso | Pfizer | Sterile, non-pyrogenic, lyophilized product. | Intravenous infusion | Enzymes | Glucocerebroside |
| 1624 | Th1137 | Teduglutide | HGDGSFSDEMNTILDNLAAR Full view | 33 | Ia | Malabsorption disorder | Gattex | NPS Pharmaceuticals, Inc | Clear, colorless to light-straw–colored liquid. | Subcutaneous injection | N.A. | Glucagon-like peptide 2 receptor |
| 1634 | Th1140 | Insulin, Isophane Or Nph Insulin (Neutral Protamine Hagedorn) | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | Novolin N | Novo Nordisk | Novolin N InnoLet (nph, human insulin isophane suspension 3 ml disposable prefilled syringe) | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
| 1666 | Th1157 | Sermorelin | YADAIFTNSYRKVLGQLSAR Full view | 30 | Ia | Hormonal | Sermorelin acetate | Emd serono inc | Sterile, non-pyrogenic, lyophilized powder | Subcutaneous Injection | Hormone Replacement Agents | Growth hormone-releasing hormone receptor |
| 1684 | Th1164 | Antithrombin Alfa | NA Full view | 0 | Ia | Hematological Disorders | Atryn | Gtc Biotherapeutics, Inc. | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | NA |
| 1685 | Th1164 | Antithrombin Alfa | NA Full view | 0 | Ia | Hematological Disorders | Atryn | R Evo Bioloigics, Inc. | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | NA |
| 1687 | Th1165 | Antithrombin III human | NA Full view | 0 | Ia | Hematological Disorders | Thrombate III | GRIFOLS USA, LLC | kit | NA | NA | NA |
| 1688 | Th1165 | Antithrombin III human | NA Full view | 0 | Ia | Hematological Disorders | Thrombate III | Grifols Therapeutics Inc | Powder for Solution | NA | NA | NA |
| 1691 | Th1165 | Antithrombin III human | NA Full view | 0 | Ia | Hematological Disorders | Thrombate III Pws IV 1000iu/vial | Miles Inc. Pharmaceutical Division | Powder for Solution | NA | NA | NA |
| 1694 | Th1166 | Asfotase Alfa | LVPEKEKDPKYWRDQAQETL Full view | 726 | Ia | Genetic Disorders | Strensiq | Alexion Pharma Ghbh | Solution | Subcutaneous | Enzymes Alimentary Tract and Metabolism | Sphingosine 1-phosphate receptor 1; Pyrophosphate |
| 1695 | Th1166 | Asfotase Alfa | LVPEKEKDPKYWRDQAQETL Full view | 726 | Ia | Genetic Disorders | Strensiq | Alexion Pharmaceuticals Inc. | Solution | Subcutaneous | Enzymes Alimentary Tract and Metabolism | Sphingosine 1-phosphate receptor 1; Pyrophosphate |
| 1704 | Th1168 | Autologous cultured chondrocytes | NA Full view | 0 | Ia | Osteological Disorders | Carticel | Genzyme Corporation | Implant | Intra-auricular | NA | NA |
| 1706 | Th1169 | Beractant | NA Full view | 0 | Ia | Respiratory | Survanta | Abb Vie Inc. | Suspension | Endotracheal | NA | NA |
| 1707 | Th1169 | Beractant | NA Full view | 0 | Ia | Respiratory Disorder | Survanta | Abbvie Corporation | Suspension | Intratracheal | NA | NA |
| 1715 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Berinert 1500 | Csl Behring Canada Inc | kit; Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
| 1717 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Cinryze | Viropharma Biologics Inc | Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
| 1719 | Th1172 | Coagulation Factor XIII A-Subunit (Recombinant) | NA Full view | 0 | Ia | Hematological Disorders | Tretten | Novo Nordisk | Kit | Intravenous | NA | NA |
| 1720 | Th1172 | Coagulation Factor XIII A-Subunit (Recombinant) | NA Full view | 0 | Ia | Hematological Disorders | Tretten | Novo Nordisk Canada Inc | Powder for Solution | Intravenous | NA | NA |
| 1722 | Th1173 | Conestat alfa | NA Full view | 0 | Ia | Genetic Disorders | Ruconest | Pharming; Santarus, Inc. | Powder for Solution | Intravenous | NA | NA |
| 1736 | Th1177 | Elosulfase alfa | APQPPNILLLLMDDMGWGDL Full view | 496 | Ia | Metabolic Disorders | Vimizim | Biomarin International Limited | Solution | Intravenous | Enzymes; Alimentary Tract and Metabolism | N-acetylgalactosamine-6-sulfatase |
| 1745 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Riastap | Csl Behring Gmb H | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | NA |
| 1746 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Artiss Frozen | Baxter Healthcare Corporation | NA | NA | NA | NA |
| 1747 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Evicel Fibrin Sealant (human) | Ethicon Inc | NA | NA | NA | NA |
| 1748 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Raplixa | Pro Fibrix Bv | NA | NA | NA | NA |
| 1749 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Tachosil | Baxter Healthcare Corporation | NA | NA | NA | NA |
| 1750 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Tisseel | Baxter Healthcare Corporation | NA | NA | NA | NA |
| 1751 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Tisseel Frozen | Baxter Healthcare Corporation | NA | NA | NA | NA |
| 1799 | Th1193 | Turoctocog alfa | NA Full view | 0 | Ia | Hematological Disorders | Zonovate | Novo Nordisk Canada Inc | sterile, non-pyrogenic, white or slightly yellow Powder | Intravenous | NA | NA |
| 1801 | Th1195 | Simoctocog Alfa | NA Full view | 0 | Ia | Hematological Disorders | Nuwiq | Octapharma Pharmazeutika Produktionsges M B H | Powder and solvent for Solution | Intravenous infusion | Antihaemorrhagics: blood coagulation factor VIII | NA |
| 1803 | Th1197 | Sebelipase alfa | SGGKLTAVDPETNMNVSEII Full view | 378 | Ia | Genetic Disorders | Kanuma | Alexion Pharmaceuticals, Inc. | Aqueous Solution | Intravenous infusion | Enzymes | NA |
| 1804 | Th1198 | Sacrosidase | NA Full view | 0 | Ia | Genetic Disorders | Sucraid | QOL Medical, LLC | Solution | Oral | Enzymes | NA |
| 1806 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Feiba Nf | Baxter Healthcare Corporation | Freeze-dried fraction | Intravenous | NA | NA |
| 1807 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Cofact | Sanquin | NA | Intravenous | NA | NA |
| 1808 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Kcentra | Csl Behring Ag | Nanofiltered and Lyophilized non-activated four-factor Prothrombin Complex Concentrate | Intravenous | NA | NA |
| 1809 | Th1200 | Prothrombin complex concentrate | NA Full view | 0 | Ia | Hematological Disorders | Octaplex | Octapharma | Powder and solvent for Solution | Intravenous | NA | NA |
| 1810 | Th1201 | Poractant alfa | NA Full view | 0 | Ia | Respiratory Disorder | Curosurf | Chiesi USA, Inc | Suspension | Endotracheal | Pulmonary Surfactants | |
| 1812 | Th1203 | Peginterferon beta-1a | NA Full view | 0 | Ia | Neurological Disorder | Plegridy | Biogen Canada Inc | Sterile Solution | Subcutaneous | NA | |
| 1821 | Th1212 | Insulin Pork | A chain GIVEQCCTSICS Full view | 68 | Ia | Metabolic Disorders | Iletin II | Lilly | sterile suspension | Subcutaneous | Hypoglycemic Agents, Antidiabetic Agents | Insulin receptor, Insulin-like growth factor 1 receptor, Insulin-degrading enzyme, HLA class II histocompatibility antigen, DQ alpha 2 chain, HLA class II histocompatibility antigen, DQ beta 1 chain, Retinoblastoma-associated protein, Cathepsin D, Carboxypeptidase E, Neuroendocrine convertase 2, Neuroendocrine convertase 1, Protein NOV homolog, Low-density lipoprotein receptor-related protein 2, Insulin-like growth factor-binding protein 7, Synaptotagmin-like protein 4, Cytochrome P450 1A2 |
| 1822 | Th1213 | Insulin Degludec | Insulin degludec dif Full view | 0 | Ia | Metabolic Disorders | Tresiba | Novo Nordisk | sterile, aqueous, clear, and colorless Solution | Subcutaneous | NA | NA |
| 1823 | Th1214 | Insulin Beef | A chain: GIVEQCCASVC Full view | 71 | Ia | Metabolic Disorders | NA | NA | NA | NA | NA | NA |
| 1827 | Th1217 | Anti-inhibitor coagulant complex | NA Full view | 0 | Ia | Hematological Disorders | Feiba Nf | NA | Solid | Intravenous | Blood Coagulation Factors, Antihemophilic Agent | NA |
| 1833 | Th1223 | Chorionic Gonadotropin (Human) | Alpha Chain: APDVQDC Full view | 237 | Ia | Hormonal Disorders | Ovidrel | Emd Serono | Injection, solution | Subcutaneous | Hormones | Lutropin-choriogonadotropic hormone receptor |
| 1834 | Th1223 | Chorionic Gonadotropin (Human) | Alpha Chain: APDVQDC Full view | 237 | Ia | Hormonal Disorders | Pregnyl | Physicians Total Care, Inc. | Injection, Solution | Intramuscular, Subcutaneous | Hormones | Lutropin-choriogonadotropic hormone receptor |
| 1835 | Th1224 | Chorionic Gonadotropin (Recombinant) | Alpha chain : APDVQD Full view | 237 | Ia | Hormonal Disorders | Ovitrelle | Merck Serono Europe Limited | powder and solvent to be made up into a solution | Subcutaneous | Hormones | Lutropin-choriogonadotropic hormone receptor, Follicle-stimulating hormone receptor |